2026-03-20T11:45:25-05:00 2025-06-30 953001179 WINDES INC 2050 MAIN ST STE 1300 IRVINE CA 92614 990 2024-07-01 953772528 PEDIATRIC CANCER RESEARCH FOUNDATION PEDI 9498596312 2151 MICHELSON DRIVE SUITE 180 IRVINE CA 92612 SCOTT ECKER TREASURER 9498596312 2026-03-18 1 1 ELEANOR A LIVINGSTON CPA MST P00226461 9498529433 2026-03-18 2024 2025-03-06 01:10:19Z SCOTT ECKER 2151 MICHELSON DRIVE SUITE 180 IRVINE CA 92612 6321349 0 X WWW.PCRF-KIDS.ORG X 1982 CA THE FOUNDATION'S MISSION IS TO IMPROVE THE CARE, QUALITY OF LIFE AND SURVIVAL RATE OF CHILDREN WITH MALIGNANT DISEASES. THE FOUNDATION RAISES FUNDS TO SUPPORT STATE-OF-THE-ART RESEARCH THAT WILL ULTIMATELY LEAD TO A CURE FOR ALL CHILDHOOD CANCERS. 16 16 9 100 0 0 1686095 4883196 0 0 38609 64553 -340355 -722925 1384349 4224824 914813 1695918 0 0 478660 1178019 0 0 1239572 519053 856306 1912526 3730243 -528177 494581 2928993 3683169 1738744 1971248 1190249 1711921 FUND RESEARCH TO POWER CURES THAT REDUCE THE PERCENTAGE OF CHILDREN WHO PERISH FROM CANCER UNTIL THAT NUMBER REACHES ZERO. 0 0 2081897 1516668 PEDIATRIC CANCER RESEARCH ACTIVITIES - PRIMARY FUNDING SOURCE FOR RESEARCH STUDIES, STAFF & EQUIPMENT NEEDS FOR PEDIATRIC CANCER RESEARCH LABS. SEE SCHEDULE I FOR ADDITIONAL DETAIL. 179250 179250 MENTAL HEALTH AND SURVIORSHIP SUPPORT. 2261147 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 8 0 1 9 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY AL AK AR CO CT FL GA HI IL KS KY MD MA MI MN MS NV NH NJ NM NC ND OH OR PA RI SC TN UT VA WV WI WA X X SCOTT ECKER TREASURER 9498596312 2151 MICHELSON DRIVE SUITE 180 IRVINE CA 92612 STEVE GIUSTO PRESIDENT 1.00 X X 0 0 0 JOHN COON VICE PRESIDENT 1.00 X X 0 0 0 SCOTT ECKER TREASURER 1.00 X X 0 0 0 BETH ABRAMS DIRECTOR 1.00 X 0 0 0 SUSIE BUCHAN DIRECTOR 1.00 X 0 0 0 TIM CROMWELL DIRECTOR 1.00 X 0 0 0 CHERIE DALY DIRECTOR 1.00 X 0 0 0 KEITH KOELLER DIRECTOR 1.00 X 0 0 0 ELIZABETH MCNULTY DIRECTOR 1.00 X 0 0 0 JASON O'DONNELL DIRECTOR 1.00 X 0 0 0 AMANDA SARATSIS MD DIRECTOR 1.00 X 0 0 0 JOHN VALLELY DIRECTOR 1.00 X 0 0 0 DARTH VAUGHN DIRECTOR 1.00 X 0 0 0 JOHN WEINER DIRECTOR 1.00 X 0 0 0 NICOLE WILKINS DIRECTOR 1.00 X 0 0 0 LEN SHULMAN DIRECTOR 1.00 X 0 0 0 JERI WILLSON EXECUTIVE DIRECTOR (THRU 10/2024) 40.00 X 188813 0 6450 DANIELLE FRAGALLA CEO 40.00 X 202223 0 7500 MORGAN MARCH SENIOR DIRECTOR OF DEVELOPMENT 40.00 X 115704 0 3372 BONNIE LATTIMORE VP OF DEVELOPMENT, STRAT. PTNRSHP 40.00 X 115038 0 3362 SAVANNAH SCHMIER SPECIAL EVENTS MANAGER 40.00 X 107508 0 1269 729286 0 21953 5 0 1 0 0 3085309 1797887 534123 4883196 64553 64553 1325000 1325000 0 48600 3085309 771525 -722925 -722925 4224824 0 0 -658372 1549668 1549668 146250 146250 287756 201429 28776 57551 763412 126694 81664 555054 21704 6775 2280 12649 24318 7591 2555 14172 80829 25231 8492 47106 100406 22587 5057 72762 247335 56177 12794 178364 190128 50180 139948 43216 6284 10581 26351 16837 3401 6719 6717 156957 48994 16491 91472 186 93 93 12283 3062 806 8415 17141 4002 2751 10388 DUES, SUBSCRIPTIONS, AN 71817 2822 50465 18530 3730243 2261147 229524 1239572 616421 559943 46950 847665 1224911 69831 111860 151673 1574083 356929 250000 250000 259848 292048 2928993 3683169 164469 207812 965847 797967 325351 641517 283077 323952 1738744 1971248 X 1190249 526234 1185687 1190249 1711921 2928993 3683169 494581 27091 0 X 0 1 X 1 0 X 3381857 3808467 4071163 1685095 4883196 17829778 3381857 3808467 4071163 1685095 4883196 17829778 348417 17481361 66 10776 25508 38609 64553 139512 48753 52706 47304 148763 18118053 371375 0.96490 0.96120 X SCHEDULE A, PART II, COLUMN E: THE ORGANIZATION CHANGED ITS FISCAL YEAR END FROM DECEMBER 31 TO JUNE 30. THE PRIOR FORM 990 COVERED A SHORT PERIOD FROM JANUARY 1, 2024 THROUGH JUNE 30, 2024. THE CURRENT RETURN COVERS THE FISCAL YEAR JULY 1, 2024 THROUGH JUNE 30, 2025. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 INVESTMENT IN ONCOHEROES BIOSCIENCES, INC. 250000 C 250000 DEPOSITS 12152 OPERATING LEASE RIGHT-OF-USE ASSET 279896 292048 OPERATING LEASE LIABILITY 323952 323952 X 4269289 27091 17374 44465 4224824 0 4224824 3747617 17374 17374 3730243 0 3730243 PART X, LINE 2: THE FOUNDATION QUALIFIES AS A TAX-EXEMPT FOUNDATION UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND UNDER THE CORRESPONDING CALIFORNIA TAX CODES. THE FOUNDATION IS ALSO REGISTERED IN THE STATES OF NEW YORK, NEW JERSEY, AND ILLINOIS. FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION (ASC) TOPIC 740, INCOME TAXES, REQUIRES MANAGEMENT TO EVALUATE THE TAX POSITIONS TAKEN BY THE FOUNDATION AND TO RECOGNIZE A TAX LIABILITY IF THE FOUNDATION HAS TAKEN AN UNCERTAIN POSITION THAT MORE LIKELY THAN NOT WOULD NOT BE SUSTAINED UPON EXAMINATION BY THE INTERNAL REVENUE SERVICE. MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE FOUNDATION AND HAS CONCLUDED THAT, AS OF JUNE 30, 2025, THERE ARE NO UNCERTAIN POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, THAT WOULD REQUIRE RECOGNITION OF A LIABILITY OR DISCLOSURE IN THE FINANCIAL STATEMENTS. THE FOUNDATION IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS. THE STATUTE OF LIMITATIONS FOR FEDERAL AND STATE PURPOSES IS GENERALLY THREE AND FOUR YEARS, RESPECTIVELY. REACHING FOR THE CURE 804939 804939 6471 3250 252514 WILL IRWIN GOLF TOURNAMENT 599692 551092 48600 10000 27831 158422 15 1729278 1729278 85839 52221 6400 168577 3133909 3085309 48600 102310 80052 9650 579513 771525 -722925 1 NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595 131099420 501(C)(3) 550000 0 PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BLVD LOS ANGELES CA 90027 951690977 501(C)(3) 37500 0 PRECLINIAL STUDY TO TRANSLATE THERAPY USING DNA HYPOMETHYLATING AGENTS FOR PEDIATRIC HIGH GRADE GLIOMAS CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BLVD LOS ANGELES CA 90027 951690977 501(C)(3) 32000 0 RESEARCH INTO MULTIDISCIPLINARY APPROACH TO SIGNIFICANTLY AND POSITIVELY IMPROVE THE QUALITY OF LIFE OF AND QUALITY OF CARE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(C)(3) 100000 0 SINGLE-CELL DISSECTING OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA DANA FARBER 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 100000 0 ADVANCING LIQUID BIOPSIES TO THE CLINIC FOR PATIENTS WITH EWING SARCOMA CASE WESTERN 10900 EUCLID AVENUE CLEVENLAND OH 44106 341018992 501(C)(3) 37500 0 USE OF MR FINGERPRINTING FOR DETERMINING RESPONSE TO IMMUNOTHERAPY IN PEDIATRIC BRAIN TUMORS MEMORIAL SLOAN KETTERING 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 150000 0 TOWARDS CURATIVE EPIGENETIC THERAPIES OF REFRACTORY PEDIATRIC SARCOMAS UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94118 946036493 501(C)(3) 45000 0 A RISK STRATIFIED CLINICAL TRIAL FOR PATIENTS WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA STANFORD 3172 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 100000 0 TARGETING MITOCHONDRIAL PATHWAYS IN PEDIATRIC AML JOHNS HOPKINS SOM 733 N BROADWAY BALTIMORE MD 21205 520595100 501(C)(3) 100000 0 TARGETING SHP2 AS A THERAPEUTIC STRATEGY IN FUSION-NEGATIVE RHABDOMYOSARCOMA INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON IN 47401 356001673 501(C)(3) 27000 0 DECODING METABOLIC DEPENDENCIES OF MPNSTS AND ITS MICROENVIRONMENT HOPE FOR HENRY FOUNDATION 2440 WISCONSIN AVE NW SUITE 201 WASHINGTON DC 20007 200244173 501(C)(3) 30000 0 REWARDING PEDIATRIC PATIENTS AND ELEVATING THEIR CARE V FOUNDATION 14600 WESTON PARKWAY CARY NC 27513 133705951 501(C)(3) 204000 0 CANCER RESEARCH RONALD MCDONALD HOUSE CHARITIES 4560 FOUNTAIN AVE LOS ANGELES CA 90029 953167869 501(C)(3) 25000 0 WILDFIRE RECOVERY FUNDING FOR FAMILIES OF CANCER PATIENTS AT THE LOS ANGELES RONALD MCDONALD HOUSE LIVE LIKE LIV FOUNDATION 3 SOUTH POINT ROAD SARATOGA SPRINGS NY 12866 272472834 501(C)(3) 8000 0 SUPPORTS CHILDREN AND FAMILIES DEALING WITH SERIOUS CONDITIONS 14 SCHOLARSHIPS 75 146250 PART I, LINE 2: ACCORDING TO ITS ESTABLISHED GUIDELINES, PCRF SUPPORTS RESEARCH INTENDED TO DEVELOP INNOVATIVE APPROACHES TO THE TREATMENT, DIAGNOSIS AND PREVENTION OF PEDIATRIC CANCER. GRANTS ARE AWARDED TO PRINCIPAL INVESTIGATORS HOLDING AN MD OR PHD DEGREE WORKING IN DOMESTIC RESEARCH INSTITUTIONS. GRANTS ARE SUBJECT TO SCIENTIFIC PEER REVIEW BY AN INDEPENDENT COMMITTEE OF ONCOLOGISTS OR SCIENTISTS AND ARE ALSO SUBJECT TO BUDGETARY CONSTRAINTS AS DETERMINED BY PCRF'S BOARD OF DIRECTORS. REVIEW CRITERIA INCLUDES: 1) THE PROBABILITY OF AN ADVANCE IN PREVENTION, DIAGNOSIS OR TREATMENT FOR THE NEAR-TERM, 2) NOVELTY OF THE CONCEPT AND STRATEGY, 3) CLARITY OF PRESENTATION, 4) EXPERIENCE AND QUALIFICATIONS OF THE INVESTIGATORS, 5) ADEQUACY OF RESOURCES AND ENVIRONMENT, AND, 6) OVERALL PLAN FOR BRINGING THE RESEARCH FINDINGS TO CLINICAL APPLICATION. FUNDING REQUESTS MUST BE CONSISTENT WITH THE OBJECTIVES OF THE PROJECT AND GENERALLY NOT INCLUDE OVERHEAD OR INDIRECT COSTS. CERTAIN GRANT PAYMENTS ARE MADE ONLY AFTER SUBMISSION AND REVIEW OF QUARTERLY REPORTS. SUBMISSION OF SCIENTIFIC RESULTS AND UPDATES MUST BE MADE ANNUALLY. X X X 0 0 0 0 0 0 0 0 0 DANIELLE FRAGALLA CEO 201923 0 0 0 300 0 7500 0 0 0 209723 0 0 0 JERI WILLSON EXECUTIVE DIRECTOR (THRU 10/2024) 188633 0 0 0 180 0 6450 0 0 0 195263 0 0 0 X 11790 FAIR MARKET VALUE X 16 401327 FAIR MARKET VALUE X 18 38477 FAIR MARKET VALUE X GIFT CARDS 38 65154 FAIR MARKET VALUE X TICKETS 7 17375 FAIR MARKET VALUE 0 0 0 PART I, COLUMN (B): THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION B, LINE 11B THE FINAL VERSION OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE AFTER THE DETAILED REVIEW IS COMPLETED BY THE FINANCIAL DIRECTOR AND THE TREASURER. THE TREASURER DISTRIBUTES A COPY OF THE FINAL VERSION OF THE FORM 990 TO THE BOARD OF DIRECTORS FOR FINAL REVIEW PRIOR TO FILING. THE RETURN IS FILED AFTER THE BOARD REVIEWS THE FORM 990. FORM 990, PART VI, SECTION B, LINE 12C ALL BOARD MEMBERS, KEY EMPLOYEES, AND MANAGEMENT ARE COVERED BY THE CONFLICT OF INTEREST POLICY. DETERMINATIONS OF CONFLICT AND REVIEW OF CONFLICT IS PERFORMED AT THESE VARIOUS LEVELS OF THE ORGANIZATION. APPROPRIATE ACTION DEPENDING ON THE CONFLICT IS TAKEN BY MANAGEMENT, KEY EMPLOYEES AND THE BOARD. DISCLOSURE FORMS ARE REQUIRED ANNUALLY BY EACH MEMBER OF THE BOARD OF DIRECTORS, KEY EMPLOYEES, AND MANAGEMENT. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE AND BOARD APPROVES COMPENSATION OF TOP MANAGEMENT. THE COMPENSATION COMMITTEE REVIEWED INDUSTRY STANDARD COMPENSATIONS. FORM 990, PART VI, SECTION C, LINE 19 THE FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. PEDIATRIC CANCER RESEARCH FOUNDATION NEW YORK A NOT FOR PROFIT CORPORATION 2151 MICHELSON DRIVE IRVINE CA 92618 273051697 FUNDING SOURCE FOR RESEARCH NY 501(C)(3) LINE 4 N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0